Cytosorbents Cor (CTSO) 0.2120 $CTSO
CytoSorbents Corp. Expands Its Product Distribution to Include the Middle East
ACCESSWIRE - Fri Apr 25, 8:51AM CDT
CytoSorbents Corp.'s (OTCQB: CTSO) stock volume surged Apr. 24, with 1,774,353 shares changing hands, higher than its three-month average volume of 1,703,870 shares.
Merriman Capital Markets Advisory Group Hosts Spotlight: Healthcare Investor Event
Thomson Reuters ONE - Wed Apr 16, 8:07AM CDT
SAN FRANCISCO - April 16, 2014 - Merriman Capital, Inc. ("Merriman"
, a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), hosted a highly engaging investor event on April 10, 2014 that highlighted three of its healthcare-focused Capital Markets Advisory Clients.
CytoSorbents Expands Distribution to the Vast Middle Eastern Market of Saudi Arabia, United Arab Emirates, and Other GCC Countries with Techno Orbits
PR Newswire - Tue Apr 08, 7:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses, announced distribution of its CytoSorb® extracorporeal cytokine filter in the Middle East, including Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Bahrain, and Oman (the Gulf Cooperation Council or GCC) and Yemen, Iraq, and Jordan through an exclusive agreement with Techno Orbits. This multi-year agreement is subject to annual minimum guaranteed orders of CytoSorb® to maintain exclusivity.
Vista Partners Publishes April 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri Apr 04, 8:00AM CDT
Vista Partners ("Vista" announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of April. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.
Merriman Capital Markets Group Hosting Healthcare Spotlight Investor Event
Thomson Reuters ONE - Thu Apr 03, 3:05PM CDT
SAN FRANCISCO - April 3, 2014 - Merriman Capital, Inc. ("Merriman", a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), is pleased to announce that it will be hosting an investor event highlighting three of its healthcare-focused Capital Markets Advisory Clients.
Oracle Hits New Yearly High; Cytosorbents Posts Record Q4 in 2013
ACCESSWIRE - Tue Apr 01, 12:57AM CDT
Oracle Corporation (NYSE: ORCL) - For an in-depth report on Oracle Corporation follow: www.BullTrends.com/stockquote/ORCL
CytoSorbents Posts Record Q4 2013 and Full Year 2013 Revenue
PR Newswire - Mon Mar 31, 3:05PM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses in the intensive care unit, provides an operational summary and financial results for the fiscal year ending December 31, 2013.
CytoSorbents to Report Fiscal 2013 Operating and Financial Results
PR Newswire - Tue Mar 25, 6:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its European Union approved CytoSorb® blood filter to treat life-threatening illnesses in the intensive care unit, will report fiscal 2013 financial results after the market close on Monday, March 31, 2014.
CytoSorbents to Sponsor CytoSorb® Research Symposium at ISICEM 2014
PR Newswire - Thu Mar 13, 5:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses in the intensive care unit, announced that it will sponsor a research symposium entitled:
CytoSorbents Corporation Announces $10,200,000 Registered Direct Offering
PR Newswire - Fri Mar 07, 8:31AM CST
CytoSorbents Corporation (OTCBB: CTSO), a Nevada corporation, today announced that it has entered into subscription agreements with certain institutional investors to sell approximately $10,200,000 of its common stock and warrants to purchase common stock in a registered direct offering.
Vista Partners Publishes March 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri Mar 07, 8:00AM CST
Vista Partners ("Vista" announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of March. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.
National Institutes of Health Grant Urges Latino Males to Receive Free Confidential HIV Testing
PR Newswire - Wed Jan 29, 7:30AM CST
Today marks the launch of "Conoces a Pepe? Have you met Pepe?," a social impact campaign focusing on educating and mobilizing Hispanic/Latino communities to live their best life with HIV testing and taking responsibility for their health.
Stryker Hits 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 9:20AM CST
Shares of Stryker Corporation were favorably affected by its announcement of acquiring Irvine, Calif.-based Patient Safety Technologies
CytoSorbents to Exhibit at the 43rd Society of Critical Care Medicine Congress and Present at the Biotech Showcase 2014
Marketwire - Tue Jan 07, 8:01AM CST
CytoSorbents Corporation (OTCBB: CTSO), a critical care immunotherapy company, announced that it will exhibit its CytoSorb(R) and HemoDefend(TM) technologies at the Society of Critical Care Medicine (SCCM) 43rd Critical Care Congress from January 10-12, 2014 at the Moscone Center South in San Francisco, California in Booth 918. More than 4,000 critical care clinicians from the U.S. and abroad are expected to attend.
CytoSorbents Reports on Successful DIVI 2013 Conference
Marketwire - Mon Dec 16, 7:31AM CST
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, reports on its recent activities at the DIVI 2013 Congress in Leipzig, Germany.
Biocon Partners With CytoSorbents to Market CytoSorb(R) -- A 'First-in-Class' Therapy for Sepsis Management
Marketwire - Fri Sep 13, 7:01AM CDT
Biocon Ltd, Asia's largest biotech company, and CytoSorbents Corporation (OTCQB: CTSO), based in the United States, announced today, World Sepsis Day, that they have entered into a strategic partnership with an initial distribution agreement for India and select emerging markets, under which Biocon will have the exclusive commercialization rights for CytoSorb(R), a novel therapy for the management of sepsis.
Stop Sepsis. Save Lives. CytoSorbents Sponsors Global Sepsis Alliance and Sepsis Heroes in Honor of World Sepsis Day
Marketwire - Thu Sep 12, 5:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a leading innovator in the use of blood purification to treat critical illnesses such as sepsis, is a proud sponsor of both the Global Sepsis Alliance and the Sepsis Heroes event hosted by the Sepsis Alliance tonight in New York City, in honor of the second annual World Sepsis Day tomorrow.
CytoSorbents Awarded $203K Phase I SBIR Contract from NHLBI/NIH for HemoDefend(TM)
Marketwire - Mon Sep 09, 11:45AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company specializing in blood purification, announced today that the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded the Company a Phase I SBIR (Small Business Innovation Research) contract to further advance its HemoDefend(TM) blood purification technology for packed red blood cell (pRBC) transfusions. The project, entitled "Elimination of blood contaminants from pRBCs using HemoDefend hemocompatible porous polymer beads," is valued at $203,351 over 6 months, with funding to start immediately.
CytoSorbents to Present at the Rodman & Renshaw Annual Global Investment Conference
Marketwire - Wed Aug 28, 8:00AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, President and Chief Executive Officer, Dr. Phillip Chan will present at the Rodman & Renshaw Annual Global Investment Conference taking place on September 8-10 in New York City.
CytoSorbents Expands CytoSorb(R) Dosing Study to Eight Clinical Trial Sites
Marketwire - Wed Aug 21, 6:00AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, announced today the formal expansion of its CytoSorb(R) dosing study to eight leading clinical trial sites in Germany.
CytoSorbents Corp. Expands Its Product Distribution to Include the Middle East
ACCESSWIRE - Fri Apr 25, 8:51AM CDT
CytoSorbents Corp.'s (OTCQB: CTSO) stock volume surged Apr. 24, with 1,774,353 shares changing hands, higher than its three-month average volume of 1,703,870 shares.
Merriman Capital Markets Advisory Group Hosts Spotlight: Healthcare Investor Event
Thomson Reuters ONE - Wed Apr 16, 8:07AM CDT
SAN FRANCISCO - April 16, 2014 - Merriman Capital, Inc. ("Merriman"
, a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), hosted a highly engaging investor event on April 10, 2014 that highlighted three of its healthcare-focused Capital Markets Advisory Clients. CytoSorbents Expands Distribution to the Vast Middle Eastern Market of Saudi Arabia, United Arab Emirates, and Other GCC Countries with Techno Orbits
PR Newswire - Tue Apr 08, 7:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses, announced distribution of its CytoSorb® extracorporeal cytokine filter in the Middle East, including Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Bahrain, and Oman (the Gulf Cooperation Council or GCC) and Yemen, Iraq, and Jordan through an exclusive agreement with Techno Orbits. This multi-year agreement is subject to annual minimum guaranteed orders of CytoSorb® to maintain exclusivity.
Vista Partners Publishes April 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri Apr 04, 8:00AM CDT
Vista Partners ("Vista"
announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of April. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary. Merriman Capital Markets Group Hosting Healthcare Spotlight Investor Event
Thomson Reuters ONE - Thu Apr 03, 3:05PM CDT
SAN FRANCISCO - April 3, 2014 - Merriman Capital, Inc. ("Merriman"
, a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), is pleased to announce that it will be hosting an investor event highlighting three of its healthcare-focused Capital Markets Advisory Clients. Oracle Hits New Yearly High; Cytosorbents Posts Record Q4 in 2013
ACCESSWIRE - Tue Apr 01, 12:57AM CDT
Oracle Corporation (NYSE: ORCL) - For an in-depth report on Oracle Corporation follow: www.BullTrends.com/stockquote/ORCL
CytoSorbents Posts Record Q4 2013 and Full Year 2013 Revenue
PR Newswire - Mon Mar 31, 3:05PM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses in the intensive care unit, provides an operational summary and financial results for the fiscal year ending December 31, 2013.
CytoSorbents to Report Fiscal 2013 Operating and Financial Results
PR Newswire - Tue Mar 25, 6:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its European Union approved CytoSorb® blood filter to treat life-threatening illnesses in the intensive care unit, will report fiscal 2013 financial results after the market close on Monday, March 31, 2014.
CytoSorbents to Sponsor CytoSorb® Research Symposium at ISICEM 2014
PR Newswire - Thu Mar 13, 5:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses in the intensive care unit, announced that it will sponsor a research symposium entitled:
CytoSorbents Corporation Announces $10,200,000 Registered Direct Offering
PR Newswire - Fri Mar 07, 8:31AM CST
CytoSorbents Corporation (OTCBB: CTSO), a Nevada corporation, today announced that it has entered into subscription agreements with certain institutional investors to sell approximately $10,200,000 of its common stock and warrants to purchase common stock in a registered direct offering.
Vista Partners Publishes March 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri Mar 07, 8:00AM CST
Vista Partners ("Vista"
announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of March. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary. National Institutes of Health Grant Urges Latino Males to Receive Free Confidential HIV Testing
PR Newswire - Wed Jan 29, 7:30AM CST
Today marks the launch of "Conoces a Pepe? Have you met Pepe?," a social impact campaign focusing on educating and mobilizing Hispanic/Latino communities to live their best life with HIV testing and taking responsibility for their health.
Stryker Hits 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 9:20AM CST
Shares of Stryker Corporation were favorably affected by its announcement of acquiring Irvine, Calif.-based Patient Safety Technologies
CytoSorbents to Exhibit at the 43rd Society of Critical Care Medicine Congress and Present at the Biotech Showcase 2014
Marketwire - Tue Jan 07, 8:01AM CST
CytoSorbents Corporation (OTCBB: CTSO), a critical care immunotherapy company, announced that it will exhibit its CytoSorb(R) and HemoDefend(TM) technologies at the Society of Critical Care Medicine (SCCM) 43rd Critical Care Congress from January 10-12, 2014 at the Moscone Center South in San Francisco, California in Booth 918. More than 4,000 critical care clinicians from the U.S. and abroad are expected to attend.
CytoSorbents Reports on Successful DIVI 2013 Conference
Marketwire - Mon Dec 16, 7:31AM CST
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, reports on its recent activities at the DIVI 2013 Congress in Leipzig, Germany.
Biocon Partners With CytoSorbents to Market CytoSorb(R) -- A 'First-in-Class' Therapy for Sepsis Management
Marketwire - Fri Sep 13, 7:01AM CDT
Biocon Ltd, Asia's largest biotech company, and CytoSorbents Corporation (OTCQB: CTSO), based in the United States, announced today, World Sepsis Day, that they have entered into a strategic partnership with an initial distribution agreement for India and select emerging markets, under which Biocon will have the exclusive commercialization rights for CytoSorb(R), a novel therapy for the management of sepsis.
Stop Sepsis. Save Lives. CytoSorbents Sponsors Global Sepsis Alliance and Sepsis Heroes in Honor of World Sepsis Day
Marketwire - Thu Sep 12, 5:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a leading innovator in the use of blood purification to treat critical illnesses such as sepsis, is a proud sponsor of both the Global Sepsis Alliance and the Sepsis Heroes event hosted by the Sepsis Alliance tonight in New York City, in honor of the second annual World Sepsis Day tomorrow.
CytoSorbents Awarded $203K Phase I SBIR Contract from NHLBI/NIH for HemoDefend(TM)
Marketwire - Mon Sep 09, 11:45AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company specializing in blood purification, announced today that the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded the Company a Phase I SBIR (Small Business Innovation Research) contract to further advance its HemoDefend(TM) blood purification technology for packed red blood cell (pRBC) transfusions. The project, entitled "Elimination of blood contaminants from pRBCs using HemoDefend hemocompatible porous polymer beads," is valued at $203,351 over 6 months, with funding to start immediately.
CytoSorbents to Present at the Rodman & Renshaw Annual Global Investment Conference
Marketwire - Wed Aug 28, 8:00AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, President and Chief Executive Officer, Dr. Phillip Chan will present at the Rodman & Renshaw Annual Global Investment Conference taking place on September 8-10 in New York City.
CytoSorbents Expands CytoSorb(R) Dosing Study to Eight Clinical Trial Sites
Marketwire - Wed Aug 21, 6:00AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, announced today the formal expansion of its CytoSorb(R) dosing study to eight leading clinical trial sites in Germany.
